Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pioglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 14/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | MPC2 | O95563 | 1/20 | 0.66 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pioglitazone SCHEMBL1489588 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL29591932 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL1162192 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL676871 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL611563 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL3689044 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL21843 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL4426214 | 0.99 | PPARG (0.98) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL21844 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL4121 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048013-A1 | PHARMACEUTICAL FORMULATION WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | CONSEJO SUPERIOR INVESTIGACION (ES) | 2026-02-19 | — | — | US | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-3813799-B1 | PHARMACEUTICAL FORMULATION WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-02-21 | — | — | EP | claimed |
| EP-3517539-B1 | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, ITS PREPARATION AND ITS USE IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TYPE I AND II DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2022-12-14 | — | — | EP | claimed |
| WO-2022255867-A1 | PROTEIN BIOMARKERS FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2022-12-08 | — | — | WO | claimed |
| US-20260060966-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER AG (DE) | 2026-03-05 | — | — | US | disclosed |
| US-20260048013-A1 | PHARMACEUTICAL FORMULATION WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | CONSEJO SUPERIOR INVESTIGACION (ES) | 2026-02-19 | — | — | US | disclosed |
| US-20260027091-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER AG (DE) | 2026-01-29 | — | — | US | disclosed |
| EP-4630819-A1 | PROTEIN BIOMARKERS FOR PROGNOSIS OF LIVER FIBROSIS | Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk Onderzoek TNO (NL) | 2025-10-15 | — | — | EP | disclosed |
| US-20250313559-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2025-10-09 | — | — | US | disclosed |
| US-20250302811-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER HEALTHCARE PHARMACEUTICALS INC. | 2025-10-02 | — | — | US | disclosed |
| US-12419838-B2 | Pharmaceutical formulation with improved solubility and bioavailability | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2025-09-23 | — | — | US | disclosed |
| US-20230040719-A1 | Pharmaceutical Formulation with Improved Solubility and Bioavailability | BIONANOPHARMA S.L. (ES) | 2023-02-09 | — | — | US | disclosed |
| WO-2022255867-A1 | PROTEIN BIOMARKERS FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2022-12-08 | — | — | WO | disclosed |
| US-11484530-B2 | Pharmaceutical compositions comprising the PPAR agonist INT-131 and Nrf2 activators | Kahrs, Bjoern Colin (CH) | 2022-11-01 | — | — | US | disclosed |
| US-20220315885-A1 | BACILLUS MEGATERIUM BIOACTIVE COMPOSITIONS AND METABOLITES | MARRONE BIO INNOVATIONS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220304312-A1 | Isolated Bacterial Strain of the Genus Burkholderia and Pesticidal Metabolites Therefrom | MARRONE BIO INNOVATIONS, INC. (US) | 2022-09-29 | — | — | US | disclosed |
| US-11384332-B2 | Bacillus megaterium bioactive compositions and metabolites | MARRONE BIO INNOVATIONS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11382331-B2 | Isolated bacterial strain of the genus Burkholderia and pesticidal metabolites therefrom | MARRONE BIO INNOVATIONS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11382331-B2 | Isolated bacterial strain of the genus Burkholderia and pesticidal metabolites therefrom | NOTUM, WASF2, WEE1 | PPARG 4328/4885CYP3A4 1322/4885RXRA 4351/4885 |
| US-20250313559-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | TNNI3, TNNT2, NDUFB3 | PPARG 923/4885CYP3A4 574/4885RXRA 789/4885 |
| US-20250302811-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | TNNI3, TNNT2, NDUFB3 | PPARG 923/4885CYP3A4 574/4885RXRA 789/4885 |
| US-20260060966-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | ALB, REN, TTR | PPARG 722/4885CYP3A4 924/4885RXRA 1418/4885 |
| US-20260027091-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | ALB, REN, TTR | PPARG 631/4885CYP3A4 1070/4885RXRA 1272/4885 |
| US-20220304312-A1 | Isolated Bacterial Strain of the Genus Burkholderia and Pesticidal Metabolites Therefrom | NOTUM, WASF2, WEE1 | PPARG 4328/4885CYP3A4 1322/4885RXRA 4351/4885 |
| US-20220315885-A1 | BACILLUS MEGATERIUM BIOACTIVE COMPOSITIONS AND METABOLITES | GZMB, VIP, BAX | PPARG 988/4885CYP3A4 2035/4885RXRA 1677/4885 |
| US-11484530-B2 | Pharmaceutical compositions comprising the PPAR agonist INT-131 and Nrf2 activators | PPARG, PPARA, PPARD | PPARG 1/4885CYP3A4 361/4885RXRA 5/4885 |
| US-11384332-B2 | Bacillus megaterium bioactive compositions and metabolites | GZMB, VIP, BAX | PPARG 988/4885CYP3A4 2035/4885RXRA 1677/4885 |
| US-20260048013-A1 | PHARMACEUTICAL FORMULATION WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | SLC34A1, SCP2, HTRA1 | PPARG 2458/4885CYP3A4 369/4885RXRA 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.